Ranked #3,365 of 8,699 institutional investors
Trails Edge Capital Partners, LP
Atlanta, GA
$568M
US stock portfolio at live prices · today −$7.0M (−1.22%)
Live prices, last trade 10:48 AM ET
- Value at quarter end (Q3 2026)
- $696M
- Change from Q2 2026
- +$66.0M (+10.48%)
- Positions
- 34 · 7 new, 5 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$28.4M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesLBRX 7.96%BMRN 7.18%TRAX 6.06%OBX 5.29%IMCR 4.96%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| LBRX LB Pharmaceuticals Inc | 1,149,240 | $45.2M | 7.96% | Reduced −25% |
| BMRN BioMarin Pharmaceutical Inc. | 667,000 | $40.8M | 7.18% | Added +30% |
| TRAX First Tracks Biotherapeutics, Inc. | 814,000 | $34.4M | 6.06% | Reduced −46% |
| OBX Obsidian Therapeutics, Inc. | 2,495,660 | $30.1M | 5.29% | New |
| IMCR Immunocore Holdings plc | 1,063,234 | $28.2M | 4.96% | Unchanged |
| CYTK Cytokinetics, Incorporated | 470,000 | $24.7M | 4.35% | Added +63% |
| TNGX Tango Therapeutics, Inc. | 1,100,000 | $24.6M | 4.32% | New |
| FDMT 4D Molecular Therapeutics, Inc. | 2,227,917 | $23.8M | 4.19% | Unchanged |
| DSGN Design Therapeutics, Inc. | 2,500,000 | $23.3M | 4.09% | Added +25% |
| NGNE Neurogene Inc. | 964,885 | $21.8M | 3.84% | Added +35% |
| CLDX Celldex Therapeutics, Inc. | 765,000 | $21.0M | 3.70% | New |
| NRIX Nurix Therapeutics, Inc. | 1,573,220 | $20.8M | 3.65% | Unchanged |
| TYRA Tyra Biosciences, Inc. | 1,000,000 | $20.2M | 3.56% | New |
| MLTX MoonLake Immunotherapeutics | 1,680,000 | $18.5M | 3.25% | Added +124% |
| XENE Xenon Pharmaceuticals Inc. | 400,000 | $15.0M | 2.65% | Reduced −9% |
| CTNM Contineum Therapeutics, Inc. | 1,693,694 | $14.9M | 2.62% | New |
| CAMP Camp4 Therapeutics Corp | 3,625,576 | $14.0M | 2.47% | Added +88% |
| INBX Inhibrx Biosciences, Inc. | 170,000 | $12.4M | 2.19% | New |
| IKT Inhibikase Therapeutics, Inc. | 9,110,112 | $12.0M | 2.11% | Added +1% |
| KLRA Kailera Therapeutics, Inc. | 942,953 | $10.8M | 1.90% | Reduced −4% |
| AVTX Avalo Therapeutics, Inc. | 1,500,000 | $10.2M | 1.79% | Added +68% |
| AURA Aura Biosciences, Inc. | 1,443,333 | $10.0M | 1.75% | Unchanged |
| IRD Opus Genetics, Inc. | 2,411,657 | $9.5M | 1.67% | Reduced −12% |
| IVA Inventiva S.A. | 2,657,997 | $8.8M | 1.55% | Unchanged |
| FTH Faeth Therapeutics, Inc. | 941,689 | $8.1M | 1.43% | Added +83% |
| XFOR X4 Pharmaceuticals, Inc. | 2,571,478 | $7.7M | 1.35% | Unchanged |
| TRDA Entrada Therapeutics, Inc. | 1,428,440 | $6.4M | 1.12% | New |
| ALT Altimmune, Inc. | 4,230,000 | $5.8M | 1.03% | Added +59% |
| IPSC Century Therapeutics, Inc. | 4,134,969 | $5.0M | 0.88% | Unchanged |
| IMA ImageneBio, Inc. | 1,094,045 | $4.1M | 0.73% | Added +288% |
| NERV Minerva Neurosciences, Inc. | 1,419,000 | $3.0M | 0.52% | Unchanged |
| PMN ProMIS Neurosciences, Inc. | 557,103 | $1.8M | 0.31% | Unchanged |
| OKUR OnKure Therapeutics, Inc. | 619,557 | $1.7M | 0.30% | Reduced −57% |
| VTVT vTv Therapeutics Inc. | 76,989 | $1.3M | 0.22% | Reduced −10% |